The Centre has approved 17 proposals for foreign direct investment (FDI) amounting to Rs 262.56 crore, which include pharmaceutical company Sanofi’s application to invest Rs 180 crore to acquire another pharma company. The company plans to invest the acquisition via internal accruals.
Meanwhile, other approvals include Rs 70 crore brought in by Augere Wireless Broadband to capitalise the balance amount of the spectrum fee earlier paid to the Department of Telecommunications, induction of Rs 7.65 crore by Na Pali Europe SARL’s in an Indian company to carry out single brand retail trading and issue and allotment of shares issued towards pre-incorporation expenses to carry out the business of manufacture of Auxillary equipment used in Plastic/Polymers processing industry worth Rs 2.54 crore by Zap Piling India, Chennai, on incorporation of the company.
In India, Sanofi operates through five entities - Sanofi India (previously known as Aventis Pharma), Sanofi-Synthelabo (India), Sanofi Pasteur India, Shantha Biotechnics and Genzyme India.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1662.75 |
| Dr. Reddys Lab | 1211.30 |
| Cipla | 1224.65 |
| Zydus Lifesciences | 925.75 |
| Lupin | 2290.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: